Navigation Links
Promising results in mice on needle-free candidate universal vaccine against various flu viruses
Date:12/8/2011

Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.

Importantly, this experimental sublingual vaccine was found to induce immunity in the lungs whereas the same vaccine administered by injection failed to do so and conferred only limited protection against experimental infection. The study, spearheaded by IVI scientist Dr. Man-ki Song and Dr. Haryoung Poo from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), was reported in the November 30th issue of the journal PLoS ONE (read the report).

Current seasonal influenza vaccines are designed to induce immunity against hemagglutinin (HA), a major component of influenza virus. Because HA undergoes frequent mutations, these vaccines have to be reformulated and manufactured every year to incorporate newly emerging influenza virus strains selected by the World Health Organization.

Due to the recent emergence of highly pathogenic influenza virus strains and the threat of a human flu pandemic, health authorities and vaccine producers are under increasing pressure to manufacture and deliver a sufficient number of vaccine doses in a short time, amid a limited global production capacity.

The influenza virus M2 has already been considered as a rational target antigen for development of a universal flu vaccine because this protein is highly conserved among the different types of influenza viruses. However, attempts to develop M2-based vaccines administered by injection have been unsuccessful.

"Sublingual vaccination with M2 induced immune responses in the lungs of mice whereas the same vaccine administered by injection failed to do so. This is probably why earlier attempts involving injection of M2-based vaccines failed to protect against influenza infection and disease," said Dr. Man-ki Song, IVI scientist and lead author of the study. "This vaccination approach offers an additional strategy to prevent influenza infection and may be used to control potential influenza pandemics."

Plans to test this vaccination approach in humans are being considered. "This study suggests that aside from being a more convenient way to immunize people, sublingual vaccination induces special immune responses in the respiratory tract which are important in protection but more difficult to generate with traditional injectable vaccines. Clearly, if these promising findings obtained in laboratory animals can be reproduced in humans, they will represent a major milestone in the IVI R&D agenda." said Dr. Cecil Czerkinsky, IVI Deputy Director-General for Laboratory Sciences.


'/>"/>
Contact: Tae Kyung Byun
tkbyun@ivi.int
82-288-11159
International Vaccine Institute
Source:Eurekalert

Related biology news :

1. More promising natural gas storage?
2. Progeria: Promising results from new gene therapy on animals
3. New method of growing high-quality graphene promising for next-gen technology
4. Study finds promising drug treatment for improving language, social function in people with autism
5. Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
6. Researcher tests promising drug on those with Down syndrome
7. Exonhit and BGI announce successful completion of a promising next-generation sequencing project
8. Grants awarded to help bring promising bioscience discoveries to market
9. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
10. 22 of Americas most promising scientists selected as 2011 Pew Scholars in the Biomedical Sciences
11. A promising new approach to autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expansion to their comprehensive training and support program, Sonalink™ remote monitoring. The inaugural ... procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Cenna ... agents for the treatment of Alzheimer’s disease, announced today it has been selected to ... 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum ...
(Date:2/9/2016)... ... 2016 , ... With a presidential election in November and the future of ... together over 500 top healthcare leaders for a night and day of debates and ... MBA students of the University of Pennsylvania’s Wharton School, will be held February 18 ...
Breaking Biology Technology: